Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.39 |
| ▸ | MTOR | P42345 | 8/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21855446 | 0.87 | MTOR (0.38) | PIK3CAPIK3CGMTORATRATRIP | |
| SCHEMBL21855466 | 0.87 | HRH4 (0.38) | GSK3BDYRK1AAHRALDH1A1 | |
| SCHEMBL20542249 | 0.76 | CYP11B2 (0.36) | AHRMEN1ALDH1A1KMT2A | |
| SCHEMBL30579319 | 0.76 | CYP11B2 (0.36) | AHRMEN1ALDH1A1KMT2A | |
| SCHEMBL21855486 | 0.76 | CYP11B2 (0.33) | AHRMEN1KMT2A | |
| SCHEMBL21855501 | 0.76 | AHR (0.35) | AHR | |
| SCHEMBL21855494 | 0.74 | HRH4 (0.39) | DYRK1AAHRALDH1A1 | |
| SCHEMBL1309069 | 0.74 | PIK3CA (0.55) | PIK3CAPIK3CGMTORPIK3CB | |
| SCHEMBL20558149 | 0.73 | AHR (0.49) | AHR | |
| SCHEMBL20557838 | 0.73 | AHR (0.33) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| CN-113272305-A | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2021-08-17 | — | — | CN | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | PIK3CA 3812/4885PIK3CG 4079/4885MTOR 4280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.